Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL

This trial studies a combination of chemotherapy and radiation therapy for patients newly diagnosed with a rare cancer of the nasal passages and throat called Natural Killer/T-cell lymphoma (ENKTL). Researchers are testing whether adding a PEG-asparaginase-based chemotherapy to radiation improves outcomes. **You may be eligible if...** - You are 18 to 75 years old - You have been newly diagnosed with ENKTL (no prior treatment) - Your disease is at an early stage (stage IE or IIE) - You are in good general health (ECOG score 0–2) - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You have received prior treatment for ENKTL - You received radiation or steroids within 4 weeks before enrollment - Your estimated survival is less than 3 months - Your blood counts or kidney/liver function do not meet minimum requirements Talk to your doctor to see if this trial is right for you.